Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
08/11/2023 | Sigilon Therapeutics, Inc. | | Other | Common Stock | 683.8k | $14.92 | $10.2M | By Flagship Ventures Fund V, L.P. | 08/11/2023 |
08/11/2023 | Sigilon Therapeutics, Inc. | | Other | Common Stock | 114k | $14.92 | $1.7M | By Flagship Pioneering Special Opportunities Fund II, L.P. | 08/11/2023 |
06/07/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 177.2k | $6.24 | $1.1M | By Flagship Ventures Fund V, L.P. | 06/06/2023 |
06/07/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 22.8k | $6.24 | $142k | By Flagship V VentureLabs Rx Fund, L.P. | 06/06/2023 |
06/06/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 181.5k | $6.31 | $1.1M | By Flagship Ventures Fund V, L.P. | 06/06/2023 |
06/06/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 22.3k | $6.31 | $140.6k | By Flagship V VentureLabs Rx Fund, L.P. | 06/06/2023 |
05/26/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 72.7k | $6.23 | $452.5k | By Flagship Ventures Fund V, L.P. | 05/24/2023 |
05/26/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 9.3k | $6.23 | $58.1k | By Flagship V VentureLabs Rx Fund, L.P. | 05/24/2023 |
05/25/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 102.2k | $6.35 | $649.5k | By Flagship Ventures Fund V, L.P. | 05/24/2023 |
05/25/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 13.1k | $6.35 | $83.4k | By Flagship V VentureLabs Rx Fund, L.P. | 05/24/2023 |
05/24/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 308.3k | $6.57 | $2M | By Flagship Ventures Fund V, L.P. | 05/24/2023 |
05/24/2023 | Sana Biotechnology, Inc. | SANA | Sale | Common Stock | 39.6k | $6.57 | $259.9k | By Flagship V VentureLabs Rx Fund, L.P. | 05/24/2023 |
09/15/2022 | Codiak BioSciences, Inc. | CDAK | Purchase | Common Stock | 722.6k | $0.00 | $0 | By Flagship Ventures Fund V, L.P. | 09/15/2022 |
09/15/2022 | Codiak BioSciences, Inc. | CDAK | Purchase | Common Stock | 210.7k | $0.00 | $0 | By Flagship V VentureLabs Rx Fund, L.P. | 09/15/2022 |
09/15/2022 | Codiak BioSciences, Inc. | CDAK | Purchase | Warrants to purchase Common Stock | 722.6k | $1.88 | $1.4M | By Flagship Ventures Fund V, L.P. | 09/15/2022 |
09/15/2022 | Codiak BioSciences, Inc. | CDAK | Purchase | Warrants to purchase Common Stock | 210.7k | $1.88 | $395.1k | By Flagship V VentureLabs Rx Fund, L.P. | 09/15/2022 |
12/08/2020 | Sigilon Therapeutics, Inc. | | Conversion | Common Stock | 8.9M | $0.00 | $0 | See Footnote | 12/08/2020 |
12/08/2020 | Sigilon Therapeutics, Inc. | | Conversion | Common Stock | 1.5M | $0.00 | $0 | See Footnote | 12/08/2020 |
12/08/2020 | Sigilon Therapeutics, Inc. | | Conversion | Series A Convertible Preferred Stock | 4.4M | $0.00 | $0 | See Footnote | 12/08/2020 |
12/08/2020 | Sigilon Therapeutics, Inc. | | Conversion | Series A-1 Convertible Preferred Stock | 4.1M | $0.00 | $0 | See Footnote | 12/08/2020 |
12/08/2020 | Sigilon Therapeutics, Inc. | | Conversion | Series B Convertible Preferred Stock | 370.4k | $0.00 | $0 | See Footnote | 12/08/2020 |
12/08/2020 | Sigilon Therapeutics, Inc. | | Conversion | Series B Convertible Preferred Stock | 1.5M | $0.00 | $0 | See Footnote | 12/08/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Common Stock | 722.3k | $0.00 | $0 | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Purchase | Common Stock | 50k | $16.00 | $800k | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Common Stock | 1.4M | $0.00 | $0 | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Purchase | Common Stock | 50k | $16.00 | $800k | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Common Stock | 1.8M | $0.00 | $0 | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Purchase | Common Stock | 50k | $16.00 | $800k | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Series A-1 Convertible Preferred Stock | 7.5M | $0.00 | $0 | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Series A-2 Convertible Preferred Stock | 8.3M | $0.00 | $0 | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Series B Convertible Preferred Stock | 1.3M | $0.00 | $0 | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Series B Convertible Preferred Stock | 2.7M | $0.00 | $0 | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Series B Convertible Preferred Stock | 3.3M | $0.00 | $0 | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Common Stock | 4.1M | $0.00 | $0 | See Footnote | 10/27/2020 |
10/27/2020 | Foghorn Therapeutics Inc. | | Conversion | Common Stock | 4.5M | $0.00 | $0 | See Footnote | 10/27/2020 |
|